Everything below concerns lyophilization. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Acylated GLP-1 receptor agonist | 31-residue synthetic peptide |
| Molecular formula | C187H291N45O59 | established for the free peptide |
| Appearance | White to off-white powder | as supplied before formulation |
| Solubility | Freely soluble in water | aqueous buffers near neutral pH |
| Typical storage | 2 to 8 degrees Celsius, protected from light | powder and solution forms differ in shelf life |
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
More studies are also needed in special populations like older adults. Another large RCT of methenamine for UTI prevention, the international European ImpresU trial in older women, which is comparing methenamine to placebo instead of against antibiotics, is underway as of 2022. Methenamine is not widely recommended by medical guidelines for UTI prevention as of 2022. However, this is expected to change in the near future due to the publication of the ALTAR trial and other new high-quality clinical trials. In addition to prescription methenamine, a lower-dose combination formulation of methenamine with the nonsteroidal anti-inflammatory drug (NSAID) sodium salicylate is available over-the-counter under brand names like Cystex for treatment and prevention of UTI symptoms. This formulation is much less-studied than prescription methenamine and little data are available to inform its use. Methenamine is provided mainly as methenamine hippurate (the hippuric acid salt) or methenamine mandelate (the mandelic acid salt). The drug is taken twice daily in the case of methenamine hippurate and four times daily in the case of methenamine mandelate. Methenamine hippurate is more popular and commonly used owing to its more convenient dosing schedule. Methenamine is taken three times daily in the case of formulations in which low-dose methenamine free base is combined with sodium salicylate. The dosing schedule of methenamine is less convenient than once-daily low-dose prophylactic antibiotics.
==== Diet ==== In addition to increased fluid intake, breastfeeding women need additional calories to support milk production. This is estimated to be upwards of 300 calories per day. Mercury in fish is an important consideration for breastfeeding women. Though fish can be a good protein source, fish also contain mercury, which can be harmful. The concentration of mercury varies by fish species.
Arsène Wenger management career statistics at Soccerbase Arsène Wenger manager profile at J.League (archive) (in Japanese) Arsène Wenger profile at Arsenal.com Arsène Wenger at Soccerway.com Arsène Wenger at WorldFootball.net Arsène Wenger at Soccerbase.com (manager) Arsène Wenger at J.League (manager) (in Japanese) Arsène Wenger at L'Équipe (in French)
The new 23rd district covers southwestern Texas, including the Big Bend, and stretches eastward through Del Rio and Uvalde to the northern San Antonio suburbs including the west side of Stone Oak, Shavano Park and Camp Bullis with a small finger extending eastward to Lackland AFB in southwest San Antonio, and also westward to the eastern fringes of the El Paso suburbs. The incumbent is Republican Tony Gonzales, who was re-elected with 62.3% of the vote in 2024. Democrats are targeting the majority Hispanic district, which has a one-third White minority, and gave Donald Trump and Ted Cruz 56.8% and 52.9% of the vote, respectively, in 2024. Republican leaders called on Gonzales to end his re-election campaign after he admitted to having a sexual relationship with a former staff member who later died by suicide, following his earlier denial of the allegations. Gonzales ended his campaign on March 5, leading to the cancellation of the runoff and making challenger Brandon Herrera the Republican nominee. Gonzales later resigned on April 13 after he was expected to face an expulsion vote alongside Democratic representative Eric Swalwell, who was accused of sexual assault. Swalwell similarly had announced his resignation on April 13, hours before Gonzales' announcement. Despite multiple other vacancies which occurred around the same time having been filled by August, governor Greg Abbott never called an emergency special election to fill this seat, likely leaving it vacant until January 2027.
Sources: en.wikipedia.org
Cave 17 (Cave of the Bodhisattva Vault) is large "central pillar" cave located near Cave 14, and high up on the rock to the right of Cave 8. It was probably the main cave of the group of caves from 14 to 19, which also includes several undecorated living quarters or viharas, and was dedicated to religious services. Su Bai dates Cave 17 to the Second Stage (395–465 CE -+65), together with Cave 14. Luo and Wang date it to 465 CE +-65. Rhie attributes Cave 17 to circa 500, based on stylistic considerations. It is a "central pillar" cave, with a small, very colorful, square cella (3.80x3.90 meters; 12 x 13 feet) with a vaulted ceiling, a central pillar with two side corridors, and a back room. These caves were possibly small chapels to nearby viharas. In Cave 17, on the lower left panel of the entrance wall, appeared a Royal family, composed of the King, Queen and two young Princes. They are accompanied by monks, and men in caftan. The relief is now in the Hermitage Museum. The King wears a crown and a triple halo, with Sasanian-type royal ribbons. He wears a long white caftan decorated with small diamond designs, and has long boots. His right hand is in front of his chest, holding an incense lamp, and he holds an akinakes sword and a red bag in the left hand. The end of a long knight's sword is visible behind the first boot. The king can be identified as a Tocharian king of Kucha. His Queen wears a long robe, and his two sons, Princes, wear ornate caftan and are fair-haired.
Valve president and Half-Life director Gabe Newell coined the name "Gordon Freeman" during a conversation with the game's writer Marc Laidlaw in his car. Laidlaw had originally named the character "Dyson Poincaré", combining the names of physicist and philosopher Freeman Dyson and mathematician Henri Poincaré. The texture for Gordon's head was "too big of a job for just one person", so Valve designers combined references from four people. An earlier model of Gordon, known as "Ivan the Space Biker", had a full beard that was subsequently trimmed. Other iterations of Gordon's concept featured different glasses, a ponytail, and a helmet. Gordon wears a special full-body hazmat suit, known as the Hazardous Environment Suit (or HEV Suit). The suit is designed to protect the user from radiation, energy discharges, and blunt trauma during the handling of hazardous materials. The suit's main feature is its "high-impact reactive armor", an electrically powered armor system that, when charged, absorbs two-thirds of the damage that Gordon would ordinarily suffer in Half-Life and 80% in Half-Life 2. A fully charged suit can survive several dozen hits from small arms and even one direct hit from an RPG. The suit can be charged by various means, and has its own oxygen supply and medical injectors, such as morphine and a neurotoxin antidote. It comes with a built-in flashlight, a radio (which frequently picks up enemy communications), various tracking devices, a compass, and a Geiger counter.
=== Orthogonal approach === It is also known as perpendicular engineering. This strategy, also referred to as "chemical synthetic biology," principally seeks to alter or enlarge the genetic codes of living systems utilising artificial DNA bases and/or amino acids. This subfield is also connected to xenobiology, a newly developed field that combines systems chemistry, synthetic biology, exobiology, and research into the origins of life. In recent decades, researchers have created compounds that are structurally similar to the DNA canonical bases to see if those "alien" or xeno (XNA) molecules may be employed as genetic information carriers. Similar to this, noncanonical moieties have taken the place of the DNA sugar (deoxyribose). In order to express information other than the 20 conventional amino acids of proteins, the genetic code can be altered or enlarged. One method involves incorporating a specified unnatural, noncanonical, or xeno amino acid (XAA) into one or more proteins at one or more precise places using orthogonal enzymes and a transfer RNA adaptor from an other organism. By using "directed evolution," which entails repeated cycles of gene mutagenesis (genotypic diversity production), screening or selection (of a specific phenotypic trait), and amplification of a better variant for the following iterative round, orthogonal enzymes are produced Numerous XAAs have been effectively incorporated into proteins in more complex creatures like worms and flies as well as in bacteria, yeast, and human cell lines.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.
The fatty diacid chain associates strongly with serum albumin, which keeps the peptide in circulation and shields it from rapid renal clearance. Bound peptide is released gradually, producing a sustained receptor signal. This mechanism also reduces the peak-to-trough variation seen with shorter-acting analogues.
The balance between peripheral receptor activation and signalling in the central nervous system is not fully resolved. The extent to which slowed gastric emptying accounts for reduced energy intake, compared with direct effects on appetite circuits, is debated. Long-term effects on lean mass and on tissues outside the gut and brain are still under study.
Long-term storage is usually at minus 20 to minus 80 degrees Celsius in a sealed, desiccated container. Working aliquots can be held briefly at 2 to 8 degrees Celsius.